Article
Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial.
Investigational new drugs - 1 Dec 2020
Nakashima Kazuhisa, Ozawa Yuichi, Daga Haruko, Imai Hisao, Tamiya Motohiro, Tokito Takaaki, Kawamura Takahisa, Akamatsu Hiroaki, Tsuboguchi Yuko, Takahashi Toshiaki, Yamamoto Nobuyuki, Mori Keita, Murakami Haruyasu
Abstract excerpt
Osimertinib is a molecularly targeted agent used to treat non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) T790M mutation. However, its efficacy and safety profile when patients have poor performance status (PS) is unknown. Therefore, we conducted an open-label, multi-center, single-arm phase II study to evaluate its efficacy and safety in EGFR T790M mutation-positive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.